Investor Presentation Q1-Q3 2020

47 Investor presentation First nine months of 2020 SUSTAIN trials with subcutaneous semaglutide SUSTAIN 1 2 3 4 5 6 7 8.1% 8.1% 8.3% 8.2% 8.4% 8.7% 8.2% Baseline -0.1 -0.4 Change in HbA1c (%) -0.5 -0.9 -0.8 -1.1 -1.2 -1.3 -1.1 -01 -1.4 -1.4 -1.5 -1.5 -1.8 -1.8-1.5 -1.6 -1.6 -1.6 1.2 92 kg 89 kg 96 kg 93 kg 92 kg 92 kg 95 kg Baseline Change in weight (kg) -4.5 -3.7 semaglutide 1.0 mg -1 -1.9 -1.9 -4.3 -6.1 semaglutide 0.5 mg -5.6 placebo -5.2 -1.4 -3.5 -3.7 -3.6 -4.9 sitagliptin 100 mg -6.4 exenatide ER glargine U100 -0.7 -6.5 dulaglutide 1.5 mg -4.6 -2.3 -3.0 dulaglutide 0.75 mg Novo NordiskⓇ * Statistically significant; SUSTAIN 1: QW sema vs placebo in drug-naïve people with T2D; SUSTAIN 2: QW sema vs sitagliptin 100 mg QD in people with T2D added to 1-2 OADS; SUSTAIN 3: QW sema vs QW exenatide ER 2.0 mg in people with T2D added to 1-2 OADS; SUSTAIN 4: QW sema vs QD insulin glargine in people with T2D added to 1-2 OADS; SUSTAIN 5: QW sema vs placebo in people with T2D added to insulin; SUSTAIN 6: QW sema vs placebo, added to standard-of-care; SUSTAIN 7: QW sema vs QW dulaglutide 75 mg and 150 mg in people with T2D added to 1-2 OADS: ER: Extended-release; QW: once weekly; QD: once daily; sema: semaglutide; T2D: type 2 diabetes, OAD: oral anti-diabetics

View entire presentation